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Testing for high-risk (hr) types of human papillomavirus (HPV) is highly sensitive as a screening test of high-grade cervical
intraepithelial neoplastic (CIN2/3) disease, the precursor of cervical cancer. However, it has a relatively low specificity. Our
objective was to develop a prediction rule with a higher specificity, using combinations of human and HPV DNA methylation.
Exfoliated cervical specimens from colposcopy-referral cohorts in London were analyzed for DNA methylation levels by pyrose-
quencing in the L1 and L2 regions of HPV16, HPV18, HPV31 and human genes EPB41L3, DPYS and MAL. Samples from 1,493
hrHPV-positive women were assessed and of these 556 were found to have CIN2/3 at biopsy; 556 tested positive for HPV16
(323 CIN2/3), 201 for HPV18 (73 CIN2/3) and 202 for HPV31 (98 CIN2/3). The prediction rule included EPB41L3 and HPV and
had area under curve 0.80 (95% CI 0.78–0.82). For 90% sensitivity, specificity was 36% (33–40) and positive predictive value
(PPV) was 46% (43–48). By HPV type, 90% sensitivity corresponded to the following specificities and PPV, respectively:
HPV16, 38% (32–45) and 67% (63–71); HPV18, 53% (45–62) and 52% (45–59); HPV31, 39% (31–49) and 58% (51–65);
HPV16, 18 or 31, 44% (40–49) and 62% (59–65) and other hrHPV 17% (14–21) and 21% (18–24). We conclude that a methyl-
ation assay in hrHPV-positive women might improve PPV with minimal sensitivity loss.
Persistent infection with high-risk (hr) human papillomavirus
(HPV) types is the main cause of cervical cancer. hrHPV
testing is becoming the preferred primary screening test
because it detects almost all women with high-grade cervical
intraepithelial neoplasia (CIN2/3), for whom treatment may
prevent cervical cancer. However, an important drawback is
low speciﬁcity and positive predictive value (PPV) compared
with cytology, which is the established cervical screening test.
It is therefore of clinical interest to develop a molecular reﬂex
test for triage that maintains the high sensitivity of HPV
testing but has better speciﬁcity. Our objective was to develop
such a prediction rule using combinations of human and
HPV DNA methylation.
Quantitative measurement of DNA methylation at CpG
sites of human or viral genes has shown promise for cervical
and other cancers.1–4 We recently showed that DNA methyl-
ation in HPV16 infections was a good predictor of CIN2/3 in
women with low-grade abnormalities detected by cervical
cytology.5 In a similar vein, research by other groups has sug-
gested using methylation of CpGs in the promoters or
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introns of human genes, including CADM, MAL, EPB41L3,
TERT, PAX1, SOX1 and LMX1.6–9 Building on this research,
the primary aim of our study was to develop a molecular test
using HPV16, HPV18, HPV31 and human gene DNA meth-
ylation to predict whether women had CIN2/3 at the time of
sampling. Around three in four cervical cancers are caused
by these three HPV types,10 and the human genes might help
to determine the others. The molecular test results may be
used to predict risk by the development of a multivariate clas-
siﬁcation score, formed as a weighted average of the methyla-
tion results. Such a score may have clinical relevance by being
used in triage to spare some women colposcopy and subse-
quent anxiety and overtreatment. The concern over missing
some high-grade disease might be addressed by repeat HPV
testing 1 year later those who are predicted to be at low risk.
Our study used two large cohorts from colposcopy-
referral populations in London, with biopsy-proven CIN2/3
status. Methylation was measured in 7 HPV16 sites in L1
and L2 regions as Ref. 5; 29 HPV18 sites in regions L2, L1,
URR and E6 and 29 HPV31 sites in regions L2, L1 and URR;
and CpGs in human genes MAL, DPYS and EPB41L3. MAL
and EPB41L3 were selected on the basis of previous data in
cervical cancer; while DPYS has shown potential in other
cancers.2,8,9 A multivariate classiﬁcation score was developed
and validated in independent data sets.
Material and Methods
Patients
The study included 1,493 women from the Predictors 1 (P1)
and 2 (P2) studies at St. Mary’s and Hammersmith Hospitals
in London, where they had been referred because of an
abnormal screening smear (persistent borderline or mild,
moderate or severe dyskaryosis). All women underwent col-
poscopic examination, with biopsy and treatment as appro-
priate. The studies were approved by the local research ethics
committees and all women analyzed provided written con-
sent; full details are available elsewhere.11,12
Specimen characteristics
Prior to colposcopy samples from a Cervex brush were placed
into PreservCyt (Hologic, Danbury, USA) and stored at
270C until the methylation assays were run. PreservCyt of
300 ml was centrifuged at 13,200 rpm for 2 min and the pellet
was resuspended in 200 ml of phosphate buffered saline. DNA
isolation and bisulﬁte conversion was according to manufac-
turer’s instructions. The genomic DNA was extracted with the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), with an
exception that DNA was eluted in 60 ml AE buffer. DNA of
250 ng was used in the bisulﬁte conversion reactions where
unmethylated cytosines were converted to uracil with the EZ
DNA methylation kit (Zymo research, Irvine).
Assay methods
Samples for HPV16, HPV18 and HPV31 methylation assays
were selected by the Linear Array (Roche Molecular Systems,
Pleasanton) and a quantitative polymerase chain reaction
(PCR) test in P1, and the BD HPV test (BD Diagnostics,
Burlington) in P2. The tests provided separate typing results,
and are functionally equivalent to other hrHPV tests.12
Methylation assays were based on PCR and quantitative
pyrosequencing as previously described.2,3,5 For HPV16, two
sets of primers in L1 and L2 from Ref. 5 were used. For
HPV18 primer sets for 8 amplicons in L2, L1, URR and E6
covering 29 CpG positions, and for HPV31 7 primer sets in L2,
L1 and URR covering 29 CpG positions were obtained using
PyroMark Assay Design software version 2.0.1.15 (Qiagen). The
number of CpGs selected for HPV16 was less than HPV18 and
HPV31 because they were preselected from earlier analysis on
HPV16.5 Primers covered dense CpG areas in a single amplicon
less than 300 bp and did not overlap any CpG dyads. The
internal control for total bisulﬁte conversion was a non-CpG
cytosine in the region for pyrosequencing. Human genes CpG
sites were tested within the vicinity of the promoters.
HPV16 DNA methylation assays were as described ear-
lier.5 The concentration of each primer for the HPV31 assays
and human genes was 0.2 mM; see Supporting Information
for HPV18 assays.
Thermal cycling conditions for HPV18 were 95C for 15
min, an optimized number of cycles: 30 sec at 94C; 30 sec at
the optimized annealing temperature; 30 sec at 72C and a ﬁnal
extension between 5 and 10 min at 72C. For HPV31, they were
95C for 15 min and then 45 cycles: 30 sec at 94C; 30 sec at the
optimized annealing temperature; 30 sec at 72C and a ﬁnal
extension between 5 and 10 min at 72C. Finally, for the human
genes, they were 95C for 15 min then 45 cycles: 30 sec at 94C;
30 sec at the optimized annealing temperature; 30 sec at 72C,
and a ﬁnal extension of 10 min at 72C.
PCRs were performed using a converted DNA equivalent
of 1,600 cells using the PyroMark PCR kit (Qiagen). The cell
genome equivalents of DNA calculations assumed 6.6 pg
DNA per diploid cell. Master mix of 12.5 ml, 2.5 ml Coral
red, 2 ml of DNA, 1 ml primer and an optimized concentra-
tion of MgCl2 adjusted with water to give a 25-ml reaction
What’s new?
While high-risk (hr) human papillomavirus (HPV) testing is a highly sensitive technique for the early detection of high grade
cervical intraepithelial neoplastic disease (CIN 2/3), its relatively low specificity and positive predictive value (PPV) limits its
utility. To improve specificity and PPV, the authors of this study developed a prediction rule based on combinations of DNA
methylation in the human gene EPB41L3 and three hrHPVs: HPV16, HPV18, and HPV31. Highly significant superior perform-
ance was obtained with the predictive rule, suggesting that methylation assays may be useful in cervical screening programs
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volume were combined. The size of the ampliﬁed DNA was
conﬁrmed by the QiaExel capillary electrophoresis instrument
(Qiagen). PCR product of 10 ml was pyrosequenced using a
PyroMarkQ96 ID (Qiagen) as Ref. 2.
In each run, a nontemplate negative control was run in
addition to a standard curve consisting of 1 pg/ml 0, 50 and
100% methylated HPV plasmid in a background of 10 ng/ml
human DNA for HPV assays. For human gene assay, the
standard curves of 0, 50 and 100% methylated human DNA
were run as positive controls. The annealing temperature and
MgCl2 concentrations were optimized by running four-
gradient PCRs with ranging temperatures 49–56 with 0.5
mM increase in MgCl2. The controls showed a clear trend
with inputs of increasing percentages of methylated versus
unmethylated DNA showing linearly higher quantitative
measurements. Observed versus expected ratios of the con-
trols were close to 1 (data not shown).
Further details of primers and PCR conditions are in Sup-
porting Information Tables 1–3.
Study design
A subset of the referral samples from the P1 (between 2005 and
2007) and P2 (2007 to 2009) studies were assayed; exclusions
were solely due to sample availability, negative hrHPV test and
cancer diagnosis (Fig. 1). The primary endpoint was histologi-
cally conﬁrmed CIN2/3, taking the highest grade of abnormality
seen in the punch or treatment biopsy specimen. Histopathology
was ﬁrst reported locally and then centrally reviewed.
The CpGs listed in Supporting Information Tables 1–3
were assessed for inclusion in a classiﬁer. HPV16, HPV18 and
HPV31 genotype positivity was also considered where results
were deﬁned positive if valid DNA methylation, including a
zero value, was detected at any of the CpGs assayed.
The rationale for sample size was based on the number of
CIN2/3 cases in the HPV18 and 31 subtypes: in earlier work
25 CIN2/3 cases gave enough power for CpG sites in HPV16.5
Statistical analysis methods
Three stages were used. First, the assay results from P1 were
analyzed, and a multivariate model was developed when blinded
to the results from P2. Second, this model was validated on the
P2 samples. Third, the model was reﬁned based on the P2 sam-
ples and practical assay considerations, and a more simple classi-
ﬁcation score was evaluated using all of the data. Logistic
regression was applied with a forward-stepwise algorithm for
the development phase, so that variables were added based on
their likelihood-ratio contributions. CpG combinations consid-
ered were based on exploratory analysis from P1, using the
mean methylation or proportion of CpGs methylated. These
were chosen because earlier analysis with HPV16 indicated that
for some sites the most information might be whether a site is
methylated or not (cf. HPV16 L2), and for others it is in the
absolute value (cf. HPV16 L1).5 Failed methylation of a CpG site
was imputed as zero methylation if methylation was detected in
other CpG sites for the gene or HPV type. Model ﬁt was
assessed using likelihood-ratio v2 statistics, and discrimination
by receiver–operating characteristics (ROCs) and the area under
the curve (AUC). Log10 p values were presented based on the v
2
statistics with one degree of freedom. HPV types were classiﬁed
based on detectable methylation, where a sample was deemed
positive if any of the CpGs was measured successfully (including
zero methylation). These methylation-positive HPV types were
tabulated by CIN categories. Plots of AUC by CpG site were
used to summarize their discrimination ability; the distributions
of methylation by CIN status at CpGs in the ﬁnal model were
also plotted. Attention was focused on 90% sensitivity cut points
because this was considered appropriate for triage, where it
might be unacceptable to miss more than 10% CIN2/3. The clas-
siﬁcation score distribution was compared by cytology categories
to assess overlap. DeLong conﬁdence intervals were used for
AUC statistics,13 and Wilson conﬁdence intervals for binary out-
comes.14 Analysis was undertaken by using the statistical soft-
ware GNU R 2.15.1.15
Results
Table 1 tabulates the HPV16, HPV18 and HPV31 types
detected by the methylation assays by CIN status. It shows
that the CIN2/3 proportion in the P1 and P2 studies was
comparable by HPV type.
Stage 1: Model development using P1
Six methylation variables were selected from the forward-
stepwise logistic regression algorithm applied in P1: (1) mean
EPB41L3, (2) mean DPYS1, (3) HPV16 score from Ref. 5
(based on CpGs in L1 and L2), (4) HPV16 methylation-assay
positivity (also includes 0% methylation), (5) mean HPV18 L2
sites 4256, 4261, 4265, 4269, 4575 and 4281 and (6) mean
HPV31 L1 sites 6352 and 6364. The CpG groupings were
partly chosen to simplify the design of an assay, because the
same primer could be used for each group. Other regions and
groupings were excluded because they did not add to the mul-
tivariable model ﬁt in P1. Figure 2 shows that the individual
CpG sites in these regions were more univariately important
than those not included such as MAL, or URR regions of
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Table 1. Summary of sample HPV results in total and in the Predictors 1 and 2 (P1 and P2) studies
Group n <CIN1 CIN1 CIN2 CIN3 CIN2/31
Total 1,493 543 (36%) 394 (26%) 183 (12%) 373 (25%) 556 (37%)
P1 618 325 (53%) 67 (11%) 61 (10%) 165 (27%) 226 (37%)
P1 HPV16 238 83 (35%) 21 (9%) 24 (10%) 110 (46%) 134 (56%)
P1 HPV31 69 30 (43%) 8 (12%) 12 (17%) 19 (28%) 31 (45%)
P1 HPV18 100 54 (54%) 13 (13%) 5 (5%) 28 (28%) 33 (33%)
P1 other 240 167 (70%) 30 (12%) 21 (9%) 22 (9%) 43 (18%)
P2 875 218 (25%) 327 (37%) 122 (14%) 208 (24%) 330 (38%)
P2 HPV16 318 53 (17%) 76 (24%) 54 (17%) 135 (42%) 189 (59%)
P2 HPV31 133 23 (17%) 43 (32%) 22 (17%) 45 (34%) 67 (50%)
P2 HPV18 101 26 (26%) 35 (35%) 17 (17%) 23 (23%) 40 (40%)
P2 other 397 125 (31%) 188 (47%) 46 (12%) 38 (10%) 84 (21%)
The number of women (n) in each group is split by CIN status and HPV result based on detectable methylation, i.e., a woman is classified to be
HPV type positive if any of the CpGs tested were successful.
1Sum of previous CIN2 and CIN3 columns.
Abbreviations: CIN: cervical intraepithelial neoplastic; HPV: human papillomavirus.
Figure 2. AUC and p values for individual CpGs, excluding failed assays (no detectable methylation). The p value is represented by the
shade of the bar, with key shown in the legend; the sample size differs between the four plots. Plot (a) is for samples that were not posi-
tive for HPV16, HPV18 or HPV31; (b) is based on specimens positive for HPV16, and so adds this particular set of HPV CpGs to the human
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which shows that all components were also multivariately sig-
niﬁcant. The ROC from the ﬁtted model in P1 is shown in Fig-
ure 4. As a large number of possible predictor variables were
assessed for inclusion in the model, the next stage was used to
verify the model performance in an independent data set.
Stage 2: Validation with P2
When applied to P2 the model derived from P1 had AUC
0.79 (95% CI 0.76–0.82), v25 220.54, p< 0.00001. As expected
the performance was slightly inferior to the ﬁtted score in P1,
but it was still promising and highly signiﬁcant. Supporting
Information Table 5 shows that all components of the model
were signiﬁcant (p values <0.05) in both training and valida-
tion datasets. The replication of the model components pro-
vides further reassurance that the classiﬁcation score provides
a real signal to predict CIN status in hrHPV positive women
with abnormal cytology.
Stage 3: Final classifier using P1 and P2
Although statistically signiﬁcant, model ﬁt suggested that DPYS
and HPV16 positivity were not practically important, so to keep
the assay and score simple they were dropped. The decision to
drop the variables was based on coefﬁcient weights in the score,
p values and sample size. For example, HPV18 was not dropped
even though it had a larger p value than DPYS when dropped
from the model in P2, because it had a smaller sample size of
101 samples, compared with 875 for the human gene DPYS. The
proposed score ﬁtted from P1 and P2 was
R538:83 EPB41L3117:23HPV16-L115:43HPV16-L2
128:13HPV31-L1110:53HPV18-L2;
where the genomic regions of HPV types are indicated following
a hyphen. The terms are the mean methylation of the CpGs
within a region, except for the proportion of CpGs methylated
in the HPV16 L2 region as in Ref. 5. Each component ranges
between 0 and 1, so that R ranges between 0 and 100.
Table 2 shows a summary of this ﬁnal model, where all
terms had (i) signiﬁcant univariate power, (ii) added to the
model in a stepwise manner and (iii) information was lost
when they were dropped from the full model.
The methylation distributions of CpGs used in the model
are shown in Figure 3, and with failure rates in Supporting
Information Table 4. The failure rates were between 0.6 and
2.0% for those not in the L2 HPV region, but they were
higher for HPV L2 region CpGs. In particular 33/128 (26%)
of controls failed in the HPV18-L2 CpGs but had detectable
methylation elsewhere; for cases this was 9/73 (12%). How-
ever, because the failure rate in controls was twice that of
cases, imputing zero methylation on such occasions actually
helped prediction performance.
The ﬁnal model ROC is shown in Figure 4, where for a
cutoff of 0.5 with 90% sensitivity, speciﬁcity was 36% (33–40)
and PPV was 46% (43–48). Thus, in triage around one in
three <CIN2 women would not need to be referred to colpo-
scopy if 10% of CIN2/3 women were allowed to be missed.
By HPV type, 90% sensitivity corresponded to the following
speciﬁcities and PPV, respectively: HPV16, 38% (32–45) and
67% (63–71); HPV18, 53% (45–62) and 52% (45–59);
HPV31, 39% (31–49) and 58% (51–65); HPV16, 18 or 31,
44% (40–49) and 62% (59–65) and other types than HPV16,
18 or 31, 17% (14–21) and 21% (18–24). Supporting Infor-
mation Tables 6–9 provide further details for 60, 70, 80 and
90% sensitivity operating points.
An investigation of the score by cytology grade showed that
the score distribution (and thereby methylation distribution) by
CIN status and cytology were quite similar. For example, normal
smears that were <CIN2 (n5 201) had a mean R score of 2.0
(interquartile range (IQR) 0.2–2.2); for mild dyskaryosis
(n5 411), the mean R score was 2.1 (IQR 0.4–2.3). A complete
summary is given in Supporting Information Table 10.
Discussion
We have developed and evaluated a new classiﬁer to predict
CIN2/3 histology from a sample taken prior to colposcopy in an
abnormal cytology referral population in London, UK. The ﬁnal
model used methylation measurements of selected CpG sites in













EPB41L3 38.8 (29.7–48.6) 152.5 (34.3) 87.4 (20.1) 152.5 (34.3)
HPV16 L1 17.2 (12.5–22.2) 214.2 (47.8) 59.4 (13.9) 174.7 (39.2) 0.18
HPV16 L2 5.4 (3.4–7.3) 190.6 (42.6) 30.1 (7.4) 26.2 (6.5) 0.24
HPV31 L1 28.1 (18.3–38.8) 31.4 (7.7) 38.5 (9.3) 35.6 (8.6) 0.10
HPV18 L2 10.5 (5.5–16.1) 14.1 (3.8) 17.8 (4.6) 17.8 (4.6) 0.28
The overall likelihood ratio v2 was 406.65. The score weights (model coefficients) and 95% CIs are scaled so that the score runs between 0 and
100. The performance of individual predictors is shown in three ways: (i) the univariate log-likelihood ratio (LR) v2 (1 df) and associated p values on
a log10 scale so that—log10 p5 1, 2 and 3, respectively, when p50.1, 0.01, 0.001, etc.; (ii) the drop in LR-v
2 when removing the variable from the
full model and (iii) the stepwise increase in LR-v2 when starting with the human gene EPB41L3, that is common to all samples, and then adding the
HPV methylation predictors to a model that includes all the variables above it in the table. The Spearman correlation coefficient between EPB41L3
and the HPV methylation predictors is also given.
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the human gene EPB41L3, and HPV late regions of HPV16-L1,
HPV16-L2, HPV18-L2 and HPV31-L1. The results conﬁrmed
earlier ﬁndings for HPV16 in a different population and with a
much larger sample set,5 and extended them to HPV18 and
HPV31,16 and to other types than HPV16, HPV18 or HPV 31
by incorporating the human gene EPB41L3.9
A three-stage design of model development, validation
and updating was used to mitigate issues associated with
overﬁtting and to retain simplicity.17 The validation ROC
from the initial model was similar at the upper speciﬁcity
points to the ﬁnal amended model, which lends credibility to
the results for this population at high sensitivity.
Our ﬁndings are directly applicable to cytology-abnormal
hrHPV1 women, where missing approximately 10% of
CIN2/3 by recalling those with R> 0.5 had speciﬁcity 36%
(33–40). This improvement in speciﬁcity was obtained
because the women with low or negligible DNA methylation
were more likely to be<CIN2. Although only approximately
17% speciﬁcity at 90% sensitivity was obtained when
EPB41L3 was methylated for women not infected with
HPV16, HPV18 or HPV31, the human gene helped to
improve classiﬁcation performance by enabling the stratiﬁca-
tion of risk at the overall 90% sensitivity cutpoint. Further, as
the sensitivity operating points decreased, EPB41L3 became
even more useful (Supporting Information Tables 6–9).
A limitation of cutpoint analysis is that women with nor-
mal cytology were not represented in our cohorts, but they
will be detected through primary hrHPV screening. Thus, the
speciﬁcity and PPV might be different for 90% sensitivity
than was observed. To help address this issue future work is
planned to examine the distribution of the developed score
in hrHPV1 women with normal cytology. However, if the
improvements seen in this cytology-abnormal hrHPV1 pop-
ulation transfer to the wider population, then they might be
practically useful if cost-effective methylation assays can be
implemented in the routine clinical setting. The methylation
Figure 3. Distribution of methylation in the CpGs selected for the final model. The boxes in (a) show the interquartile range and median when
methylated in <CIN2 (white) and CIN2/3 (black) when methylated. The bars in (b) show the proportion of individuals methylated (values
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tests could be performed on the original samples in a reﬂex
manner and may reduce subsequent anxiety and overtreat-
ment in some women spared colposcopy. Concern over miss-
ing approximately 10% of CIN2/3 might be addressed by
referring women predicted to be low risk by the DNA meth-
ylation classiﬁer to repeat HPV testing in 1 year. Only a very
small proportion of CIN2/3 with low methylation would be
expected to progress to cancer within a year, and our earlier
results in Ref. 5 suggested that HPV16 L1 methylation might
also predict persistence.
The proportion of CIN2/3 was greater for multiple infec-
tions than for single infections (data not shown). This pro-
vided some support to the model assumption that multiple
infections act independently, so that, for example, a woman
with high methylation in HPV16 and HPV18 is more likely
to be CIN2/3 than one with only high methylation in
HPV16. However, a larger data set would be needed to verify
whether the classiﬁer might be improved by a more
sophisticated model for type-speciﬁc interactions.
An issue raised by the results is that L2 PCRs in HPV16
and HPV18 had a poorer success rate than L1 (Supporting
Information Table 4). A possible reason for L2 failing is that
the PCR primers had a lower ampliﬁcation efﬁciency than
the L1 primers. Another possibility is that L2 may be more
prone to deletions than L1 as the virus integrates into the
host genome. Integration of HPV16 and HPV18 occur
mostly in cancers but also in some CIN3, while integration
of HPV31 and other hrHPVs have been documented less fre-
quently.18 Also, L2 commonly failed in the assays where L1
also failed, and the low viral load in low-grade lesions in
combination with the lower ampliﬁcation efﬁciency of L2 pri-
mers might explain why imputation of 0% methylation was
useful for classiﬁcation.
The ﬁnal model may be implemented to clinical tests in
practice by the design of a suitable assay. Although multiple
PCRs are required for the assay, CpGs selected for each com-
ponent in the ﬁnal model are in the same amplicon, which
facilitates the design of an assay for clinical testing.
A strength of the current study is that the HPV16 DNA
methylation classiﬁer from Ref. 5 has been extended to other
hrHPV1 women, by incorporating a human gene and by
examining a wide range of CpG sites for HPV18 and
HPV31. Further, the number of CIN2/3 cases for HPV sub-
types appears to be greater than previous studies in the ﬁeld.
For example, the sample size for HPV18 and HPV31 pro-
vided more power to detect a methylation marker than in
our previous studies5,16; the number of HPV16 CIN2 and
CIN3 was also much greater than previous analysis of this
type, including.3 A limitation is that the analysis was based
on referral cohorts rather than a primary hrHPV screening
group. More work is needed to help address the issues this
raises for triage, and to further validate the model.
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